Overall, PSMA-PET/CT detected distant metastasis in 84 of 182 cases (46%) that were negative by other types of imaging, ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Hundreds of Australians with breast and prostate cancer will benefit from new treatments being added to the Pharmaceutical ...

A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

The study found that Focal One's treatment methods match up with the gold star standard of surgery, and improve quality of life outcomes.

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming ... [2] However, the advent of several new agents has improved both the prognosis ...

King Charles and Queen Camilla stepped out for church at Sandringham in their first joint appearance of 2025 as the King's ...

Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients ... may be overcome by new active drugs such as ...

Almost three in five cancers - including breast, prostate and lung - are being found at stages one or two, when treatment is ...